
LB Pharmaceuticals Inc (NASDAQ:LBRX – Free Report) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of LB Pharmaceuticals in a research report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($5.98) per share for the year, down from their previous forecast of ($5.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($6.05) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($1.57) EPS, Q2 2027 earnings at ($1.33) EPS, Q3 2027 earnings at ($1.24) EPS, Q4 2027 earnings at ($1.30) EPS and FY2027 earnings at ($5.44) EPS.
LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.79) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.18).
Read Our Latest Report on LB Pharmaceuticals
LB Pharmaceuticals Stock Performance
Shares of LBRX stock opened at $42.46 on Wednesday. LB Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $50.16. The stock’s 50-day simple moving average is $40.28 and its 200-day simple moving average is $33.37.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Calamos Advisors LLC purchased a new position in shares of LB Pharmaceuticals in the first quarter worth about $593,000. Profund Advisors LLC purchased a new stake in LB Pharmaceuticals in the third quarter valued at approximately $1,082,000. Sigma Planning Corp purchased a new stake in LB Pharmaceuticals in the third quarter valued at approximately $1,151,000. Great Lakes Advisors LLC purchased a new stake in LB Pharmaceuticals in the second quarter valued at approximately $987,000. Finally, Alps Advisors Inc. increased its holdings in LB Pharmaceuticals by 46.8% in the 3rd quarter. Alps Advisors Inc. now owns 42,732 shares of the company’s stock worth $1,640,000 after buying an additional 13,630 shares during the period.
LB Pharmaceuticals News Summary
These are some of the LBRX news items that stood out recently:
- Positive Sentiment: HC Wainwright maintained its Buy rating and slightly improved several 2027 EPS forecasts, including its full-year estimate to a loss of $5.44 per share from $5.48. These modest reductions in projected losses are a positive signal. LB Pharmaceuticals coverage
- Neutral Sentiment: Zacks Research upgraded LBRX from “strong sell” to “hold.” This is an improvement in sentiment, though the new rating remains cautious. Zacks Research ratings
- Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $5.98 from $5.47, and cut its Q4 2026 and Q1 2027 forecasts. The revisions indicate greater expected losses in the nearer term, tempering the more favorable 2027 changes.
LB Pharmaceuticals Company Profile
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.
Recommended Stories
- Five stocks we like better than LB Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for LB Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LB Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
